PAULO SCHIAVOM DUARTE
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/43 - Laboratório de Medicina Nuclear, Hospital das Clínicas, Faculdade de Medicina
LIM/43 - Laboratório de Medicina Nuclear, Hospital das Clínicas, Faculdade de Medicina
6 resultados
Resultados de Busca
Agora exibindo 1 - 6 de 6
- Prognostic Value of Bone Marrow Uptake Using 18F-FDG PET/CT Scans in Solid Neoplasms(2022) TUSTUMI, Francisco; ALBENDA, David Gutierrez; PERROTTA, Fernando Simionato; SALLUM, Rubens Antonio Aissar; RIBEIRO JUNIOR, Ulysses; BUCHPIGUEL, Carlos Alberto; DUARTE, Paulo SchiavomBackground: Fluorine-18-fluorodeoxyglucose positron emission tomography/computerized tomography (18F-FDG PET/CT) uptake is known to increase in infective and inflammatory conditions. Systemic inflammation plays a role in oncologic prognosis. Consequently, bone marrow increased uptake in oncology patients could potentially depict the systemic cancer burden. Methods: A single institute cohort analysis and a systematic review were performed, evaluating the prognostic role of 18F-FDG uptake in the bone marrow in solid neoplasms before treatment. The cohort included 113 esophageal cancer patients (adenocarcinoma or squamous cell carcinoma). The systematic review was based on 18 studies evaluating solid neoplasms, including gynecological, lung, pleura, breast, pancreas, head and neck, esophagus, stomach, colorectal, and anus. Results: Bone marrow 18F-FDG uptake in esophageal cancer was not correlated with staging, pathological response, and survival. High bone marrow uptake was related to advanced staging in colorectal, head and neck, and breast cancer, but not in lung cancer. Bone marrow 18F-FDG uptake was significantly associated with survival rates for lung, head and neck, breast, gastric, colorectal, pancreatic, and gynecological neoplasms but was not significantly associated with survival in pediatric neuroblastoma and esophageal cancer. Conclusion: 18F-FDG bone marrow uptake in PET/CT has prognostic value in several solid neoplasms, including lung, gastric, colorectal, head and neck, breast, pancreas, and gynecological cancers. However, future studies are still needed to define the role of bone marrow role in cancer prognostication.
- 18F-FDG-PET/CT-measured parameters as potential predictors of residual disease after neoadjuvant chemoradiotherapy in patients with esophageal carcinoma(2022) TUSTUMI, Francisco; ALBENDA, David Gutiérrez; SALLUM, Rubens Antonio Aissar; NAHAS, Sergio Carlos; RIBEIRO JUNIOR, Ulysses; BUCHPIGUEL, Carlos Alberto; CECCONELLO, Ivan; DUARTE, Paulo SchiavomAbstract Objective: To evaluate the maximum and mean standardized uptake values, together with the metabolic tumor value and the total lesion glycolysis, at the primary tumor site, as determined by 18F-fluorodeoxyglucose positron-emission tomography/computed tomography (18F-FDG-PET/CT), performed before and after neoadjuvant chemoradiotherapy (nCRT), as predictors of residual disease (RD) in patients with esophageal cancer. Materials and Methods: The standardized uptake values and the volumetric parameters (metabolic tumor value and total lesion glycolysis) were determined by 18F-FDG-PET/CT to identify RD in 39 patients before and after nCRT for esophageal carcinoma. We used receiver operating characteristic curves to analyze the diagnostic performance of 18F-FDG-PET/CT parameters in the definition of RD. The standard of reference was histopathological analysis of the surgical specimen. Results: Eighteen patients (46%) presented RD after nCRT. Statistically significant areas under the curve (approximately 0.72) for predicting RD were obtained for all four of the variables evaluated after nCRT. Considering the presence of visually detectable uptake (higher than the background level) at the primary tumor site after nCRT as a positive result, we achieved a sensitivity of 94% and a specificity of 48% for the detection of RD. Conclusion: The use of 18F-FDG-PET/CT can facilitate the detection of RD after nCRT in patients with esophageal cancer.
- Whole-Skeleton SUVmean Measured on F-18-NaF PET/CT Studies as a Prognostic Indicator in Patients with Breast Cancer Metastatic to Bone(2022) MARIN, Jose Flavio Gomes; DUARTE, Paulo Schiavom; ORDONES, Monique Beraldo; SADO, Heitor Naoki; SAPIENZA, Marcelo Tatit; BUCHPIGUEL, Carlos AlbertoIn this work, we assessed the association between the whole-skeleton SUVmean measured on F-18-NaF PET/CT studies and overall survival (OS) in patients with breast cancer metastatic to bone. Methods: We retrospectively analyzed 176 patients with breast cancer and metastatic bone disease who underwent F-18-NaF PET/CT. The outcomes of the patients (dead or alive) were based on the last information available in their files. The SUVmean and SUVmax were measured in a whole-skeleton volume of interest (wsVOI). The wsVOI was based on the CT component of the PET/ CT study using Hounsfield unit thresholds. The wsVOI was then applied to the F-18-NaF PET image. Univariate analyses were performed to assess the association of SUVs with OS. We also analyzed the association between OS and patient age; presence of visceral metastatic disease; histologic subtype; presence of hormone receptors; human epidermal growth factor receptor 2 expression; and creatinine, cancer antigen (CA) 15-3, and alkaline phosphatase levels. The variables statistically significant in the univariate analyses were included in a multivariate Cox regression OS analysis. Results: In the univariate analyses, there were associations between OS and whole-skeleton SUVmean and SUVmax, estrogen receptor status, and CA15-3 and alkaline phosphatase levels. In the multivariate analysis, all variables that were statistically significant in the univariate analyses were associated with OS, with the exception of CA15-3. Conclusion: In patients with breast cancer metastatic to bone, whole-skeleton SUVmean is an independent predictor of OS.
- A VISION of ALSYMPCA(2022) DUARTE, Schiavom
conferenceObject Dynamic F-18-Sodium Fluoride (18F-NaF) PET/CT analysis: a comparison between oral and intravenous 18F-NaF administration in the assessment of breast and prostate cancer patients(2022) ROCHA, N. H.; SADO, H.; BUCHPIGUEL, C. A.; DUARTE, P. S.; SAPIENZA, M. T.